BioXcel Therapeutics (BTAI) Long-Term Debt Issuances (2017 - 2022)
BioXcel Therapeutics' (BTAI) quarterly Long-Term Debt Issuances came in at $30.0 million in Q3 2022, up 8186.25% quarter-over-quarter from -$371000.0 in Q1 2018.
BioXcel Therapeutics (BTAI) Long-Term Debt Issuances (2017 - 2022) Analysis & Trends
BioXcel Therapeutics' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $30.0 million for Q3 2022.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $30.0 million in Q3 2022; TTM through Dec 2022 was $30.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $98.6 million, changed N/A from the prior year.
- Long-Term Debt Issuances grew to $30.0 million in Q3 2022 per BTAI's latest filing, from -$371000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $30.0 million in Q3 2022 and bottomed at -$371000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.64 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 30.00 Mn |
| Sep 30, 2022 | 30.00 Mn |
| Mar 31, 2018 | -371,000.00 |
| Mar 31, 2018 | -371,000.00 |
| Dec 31, 2017 | 2,000.00 |
| Dec 31, 2017 | 2,000.00 |
| Sep 30, 2017 | 84,000.00 |
| Sep 30, 2017 | 84,000.00 |